Surrozen (NASDAQ:SRZN) Director Buys $246,906.00 in Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 12,470 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was bought at an average price of $19.80 per share, for a total transaction of $246,906.00. Following the acquisition, the director owned 996,502 shares of the company’s stock, valued at $19,730,739.60. This represents a 1.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Tim Kutzkey also recently made the following trade(s):

• On Wednesday, January 14th, Tim Kutzkey purchased 5,523 shares of Surrozen stock. The stock was bought at an average cost of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 6th, Tim Kutzkey acquired 15,100 shares of Surrozen stock. The stock was bought at an average price of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The shares were purchased at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey bought 5,266 shares of Surrozen stock. The shares were purchased at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey acquired 315,457 shares of Surrozen stock. The shares were purchased at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Price Performance

NASDAQ:SRZN opened at $20.00 on Friday. The firm’s 50-day moving average price is $18.70 and its 200-day moving average price is $13.95. The company has a market capitalization of $171.40 million, a PE ratio of -0.90 and a beta of 0.58. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The business had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. Equities analysts anticipate that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SRZN. Wall Street Zen raised Surrozen to a “sell” rating in a research report on Friday, November 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Finally, Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Hedge Funds Weigh In On Surrozen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares during the last quarter. Stonepine Capital Management LLC boosted its holdings in Surrozen by 7.1% in the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares during the last quarter. Stempoint Capital LP boosted its holdings in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after purchasing an additional 445,713 shares during the last quarter. Armistice Capital LLC bought a new stake in Surrozen in the 2nd quarter worth approximately $536,000. Finally, Braidwell LP purchased a new stake in Surrozen during the 2nd quarter valued at $1,252,000. Institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.